|Dr. Sean Emerson George Ph.D.||Co-Founder, Pres, CEO & Director||451.35k||625.9k||1974|
|Mr. Kenneth D. Knight||Chief Operating Officer||428.5k||N/A||1961|
|Mr. Lee Bendekgey||Chief Policy Officer||383.64k||2.07M||1958|
|Ms. Yafei Wen||Chief Financial Officer||N/A||N/A||1972|
|Mr. Robert F. Werner||Chief Accounting Officer & Principal Accounting Officer||N/A||N/A||1973|
|Mr. Karthik Suri||Chief Product & Technology Officer||N/A||N/A||N/A|
|Ms. Laura D'Angelo||Head of Investor Relations||N/A||N/A||N/A|
|Dr. Robert L. Nussbaum||Chief Medical Officer||N/A||N/A||1950|
|Glenn Medalle||Head of Talent||N/A||N/A||N/A|
Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. It has a collaboration with Pacific Biosciences of California, Inc. to develop a production-scale high-throughput HiFi sequencing platform. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Invitae Corporation’s ISS governance QualityScore as of 26 September 2021 is 6. The pillar scores are Audit: 6; Board: 3; Shareholder rights: 7; Compensation: 8.